During the three months ended March 31, 2025, the global economy trended toward recovery, though uncertainty stemming from the U.S. tariff policies heightened concerns about a downturn. In the United States, the economy expanded, but downside risks increased due to weakening sentiment toward consumer spending and capital investment. In Europe, despite signs of  recovery driven by monetary easing, the economy came to a temporary standstill due to sluggish external demand. In China, although the economy showed a moderate recovery driven by policy measures, domestic demand remained sluggish, and the overall economic recovery lacked momentum. Meanwhile, the Japanese economy recovered moderately due to firm capital investments, among other factors.
Under these conditions, during the three months ended March 31, 2025, product demand remained steady in the Industrial Materials and the Medical Technologies segments, despite a sluggish demand for tablets in the Devices segment. In addition, the company acquired in the pharmaceutical business during the current period has begun to contribute to earnings.
As a result, regarding the financial results for the three months ended March 31, 2025, net sales were ¥47,442 million (an increase of 1.5% as compared to the same period of the previous year), operating profit was ¥1,509 million (an increase of 19.9% as compared to the same period of the previous year) and profit attributable to owners of parent was ¥87 million (a decrease of 92.8% as compared to the same period of the previous year).